Eagle Pharmaceuticals, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 98
Rang # Quantité totale PI 13 499
Note d'activité PI 2,7/5.0    64
Rang # Activité PI 11 281
Symbole boursier
ISIN US2697961082
Capitalisation 51.20M  (USD)
Industrie Drug Manufacturers - Specialty & Generic
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

48 10
11 2
23 4
0
 
Dernier brevet 2025 - Use of remimazolam for pediatric...
Premier brevet 2007 - Alcohol free formulation of arga...
Dernière marque 2024 - JOARCA
Première marque 2014 - EAGLE PHARMACEUTICALS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 P/S Pharmaceuticals for the treatment of cancer
Invention Use of remimazolam for pediatric sedation. The application is directed to methods of sedating a p...
Invention Formulations of bendamustine. Long term storage stable bendamustine-containing compositions are ...
Invention Formulations of bendamustine. Long term storage stable bendamustine-containing compositions are d...
2023 Invention Fulvestrant formulations. Fulvestrant formulations suitable for intramuscular injection at conce...
Invention Pemetrexed formulations. The present invention is directed to pemetrexed formulations comprising ...
Invention Pemetrexed formulations. The present invention is directed to pemetrexed formulations comprising...
Invention Formulations of bendamustine. Methods of treatment using bendamustine formulations designed for ...
Invention Fulvestrant formulations and methods of their use. The present disclosure provides methods of tre...
2021 Invention Methods of using dantrolene to treat nerve agent exposure. The disclosure is directed to methods...
Invention Fulvestrant formulations. Long term storage stable fulvestrant-containing compositions are discl...
P/S Pharmaceutical preparations for the treatment of cancer
Invention Fulvestrant formulations and methods of their use. The disclosure is directed to fulvestrant for...
Invention Methods of treating viral infections. The disclosure is directed to methods of using dantrolene ...
Invention Methods of treating severe acute respiratory syndrome. The disclosure is directed to methods of ...
Invention Methods of treating sars-cov-2 infections. The disclosure is directed to methods of using dantro...
Invention Methods of treating coronavirus infections. The disclosure is directed to methods of using dantr...
Invention Methods of treating severe acute respiratory syndrome. The disclosure is directed to methods of u...
Invention Methods of treating sars-cov-2 infections. The disclosure is directed to methods of using dantrol...
Invention Methods of treating coronavirus infections. The disclosure is directed to methods of using dantro...
Invention Methods of treating viral infections. The disclosure is directed to methods of using dantrolene o...
P/S Pharmaceuticals for cancer.
P/S Pharmaceuticals for cancer.
2020 P/S Pharmaceutical preparations for treatment of lung cancer
2019 Invention Use of dantrolene and dantrolene prodrugs to treat radiation exposure. The disclosure is directed...
Invention Dantrolene formulations and methods of their use. The disclosure is directed to liquid formulati...
Invention Dantrolene formulations and methods of their use. The disclosure is directed to liquid formulatio...
P/S Printed educational materials, namely, circulars, brochures and pamphlets on medical conditions,...
2018 P/S Printed educational materials, namely, circulars, brochures and pamphlets on medical conditions, ...
2014 P/S Commercialization of pharmaceutical products, namely, marketing in the field of pharmaceutical pr...